Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 MAY 25 ... BioCryst Pharmaceuticals (NASDAQ:BCRX) announced long-term data from a Phase 2 study of forodesine, the Company's lead oncology compound, in patients with cutaneous T-cell lymphoma ...
2009 JAN 5 ... BioCryst Pharmaceuticals (NASDAQ:BCRX) announced interim data from the ongoing Forodesine HCl Phase 2 program in patients with chronic lymphocytic leukemia (CLL) and data from a ...
2009 MAY 18 ... program, a reduction in manufacturing costs associated with both the peramivir and forodesine programs and a reduction in costs incurred related to the Company's preclinical ...
2009 FEB 16 ... program, a reduction in manufacturing costs associated with both the peramivir and Forodesine HCl programs and a reduction in costs incurred related to the Company's preclinical ...
2009 AUG 10 ... "Our efforts at BioCryst remain focused on moving our leading peramivir and forodesine clinical development programs forward," said Jon P. Stonehouse, President and Chief ...
2009 NOV 9 ... program, offset by reductions in clinical development costs for our peramivir and forodesine programs. In addition, general operating costs as well as personnel related costs were ...
2009 AUG 17 ... purine analogs and agents that interfere with the purine metabolic pathway (e.g. forodesine), immunomodulatory agents, proapoptotic small molecules (e.g. oblimersen, obatoclax, and ...
2009 FEB 2 ... the proteasome inhibitor bortezomib; and the purine nucleoside phosphorylase inhibitor forodesine. Even agents considered to be conventional chemotherapy, such as gemcitabine or ...
2009 OCT 12 ... because deletions of ATM or p53 identify CLL patients with resistance to treatment. Forodesine is a transition-state inhibitor of the purine nucleoside phosphorylase with antileukemic ...
2008 MAR 17 ... clarity in terms of the progress made in each of our lead product programs, peramivir, forodesine HCl and BCX-4208," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "Each ...
2008 NOV 10 ... program, a reduction in manufacturing costs associated with both the peramivir and forodesine HCl program and a reduction in costs incurred related to the Company's preclinical ...
2008 JUN 23 ... the recent development of novel purine nucleoside analogues (clofarabine, nelarabine and forodesine) and pyrimidine nucleoside analogues (troxacitabine, sapacitabine, CP-4055, ...
2008 FEB 4 ... of intracellular deoxyguanosine 5'-triphosphate, inducing cellular apoptosis. Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown ...
2008 JUN 30 ... is now available. According to a study from the United States, "Immucillin-H (BCX-1777, forodesine) is a transition state analogue and potent inhibitor of PNP that shows promise as a ...
2008 FEB 4 ... 'Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine,' are detailed in a study published in Seminars In Oncology. According to recent ...
2008 JUN 30 ... for both peramivir, our product for seasonal and life-threatening influenza, and forodesine HCl, being developed for oncology indications. Bill has extensive experience bringing ...
